Guosheng Du

机构：Beijing Chao-Yang Hospital, Capital Medical University, General Hospital of Shenyang Military Region

发表论文 40 篇 · 总被引 207 次 · h-index 10

代表论文

• The advantage of Sirolimus in amplifying regulatory B cells and regulatory T cells in liver transplant patients (2019 · European Journal of Pharmacology · 被引 27)
• Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma (2022 · World Journal of Gastroenterology · 被引 25)
• Prognostic Value of Preoperative NLR and Vascular Reconstructive Technology in Patients With Pancreatic Cancer of Portal System Invasion: A Real World Study (2021 · Frontiers in Oncology · 被引 20)
• PD-L1 + NEUT, Foxp3 + Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma (2021 · Technology in Cancer Research & Treatment · 被引 19)
• Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: A single center experience (2018 · Oncology Letters · 被引 17)
• Reduction of FoxP3+ Tregs by an immunosuppressive protocol of rapamycin plus Thymalfasin and Huaier extract predicts positive survival benefits in a rat model of hepatocellular carcinoma (2020 · Annals of Translational Medicine · 被引 15)